The European Commission granted Eli Lilly’s and Boehringer Ingelheim’s Jardiance (empagliflozin) marketing authorization for treating adult patients suffering from heart failure with preserved ejection fraction.

Jardiance is the first approved treatment in Europe for all adult patients with symptomatic chronic heart failure regardless of left ventricular ejection fraction status.

The approval was supported by results of a 5,988-participant phase 3 trial in which Jardiance reduced the relative risk of heart failure-related death or hospitalization by 21 percent vs. placebo.

In late February, the FDA granted Jardiance an expanded indication for treating adults with heart failure regardless of left ventricular ejection fraction.